Login Register
icon_bulk_orderBulk order Acrobiosystems for ChineseChinese
Recombinant Proteins ClearClear history
Recombinant Proteins CloseClose
Browse Products By Molecule Name a-zA-Z
SARS-CoV-2  lambda  Delta | Claudin 18.2 | CD20 | CD3 | FcR | IL-2R
0
There is no goods in the shopping cart !
My Cart
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > COVID-19 R&D
COVID-19 R&D
News
Exhibitions
Promotion
Where do we go from here: A reflection of COVID-19
2021/09/10     Read: 2768
Binding and neutralizing antibodies correlated with COVID-19 risk and vaccine efficacy
2021/08/13     Read: 2091
What You Should Know About the Lambda Variant
2021/08/12     Read: 6745
Accelerated Progress: Spike Protein Mutations on B.1.617 Identified and Studied
After the sharp rise in COVID-19 cases and deaths in India over recent weeks, at least 20 countries have imposed travel bans and restrictions to and from India. The world again stands at a crossroad of the viral evolution.
2021/05/11     Read: 5567
ACROBiosystems makes donations to BEI Resources, accelerating the process of attacking SARS-CoV-2 variants globally
Multiple SARS-CoV-2 variants are emerging and circulating globally; the battle against COVID-19 pandemic is still challenging. Recently, ACROBiosystems donated SARS-CoV-2 mutant proteins to BEI Resources, a NIAID funded bioresource program, joining in the collective effort in attacking SARS-CoV-2 va
2021/05/10     Read: 1814
The B.1.617 is Likely Behind the Recent Surge of COVID-19 Cases in India
How dangerous is the Indian ‘double mutant’ of SARS-CoV-2?
2021/04/26     Read: 6817
The importance of N protein variants in antibody test and drug design
2021/04/14     Read: 1928
Have you noticed that NTD could be a pivotal player during infection?
2021/03/12     Read: 1429
One jab and you’re done! CanSino and Johnson & Johnson adenovirus vaccines receive regulatory approval.
2021/03/08     Read: 2203
A year later: What we know about SARS-CoV-2 infectivity and growing concerns of emerging variants
It has been a year since the COVID-19 pandemic began and plethora of research into SARS-CoV-2 has led to development of vaccines and therapeutics. In this article, we review what we’ve known about SARS-CoV-2 and COVID-19, the developments in fighting the pandemic and the threat of emerging variants.
2021/03/01     Read: 14307
More

This web search service is supported by Google Inc.

totop
Call us
Call us
North America: +1 800-810-0816 (Toll Free)
Asia & Pacific: +86 400-682-2521
Email
Email
order@acrobiosystems.com
Fax
Fax
+1 888-377-6111
Address
Address
1 Innovation Way, Newark, DE 19711, USA
linkedin twitter facebook

Leave a message

Copyright © 2017 ACROBiosystems. All Rights Reserved
中文网站|Related Links|Privacy Policy|Terms and Conditions|Legal|Sitemap